Drugs that contain Ozanimod Hydrochloride

1. List of Zeposia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481573 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

US8796318 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9382217 CELGENE INTL Modulators of sphingosine phosphate receptors
May, 2029

(6 years from now)

US10239846 CELGENE INTL Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 27, 2024
New Chemical Entity Exclusivity (NCE) Mar 25, 2025

NCE-1 date: March, 2024

Market Authorisation Date: 25 March, 2020

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Indicated for the treatment of moderately to severely active ulcerative colitis

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in